March 4, 2014
/PRNewswire/ -- ANI Pharmaceuticals, Inc. (the "Company") (NASDAQ: ANIP) today announced that it intends to offer its common stock in a registered public offering pursuant to its existing shelf registration statement under the Securities Act of 1933, as amended. The Company also intends to grant the underwriters of the offering an option to purchase additional shares of common stock to cover over-allotments, if any. The Company plans to use the proceeds from the offering to research, develop, commercialize and expand its drug products, to acquire complementary businesses and technologies and for working capital and general corporate purposes. Oppenheimer & Co. Inc. and Roth Capital Partners are acting as joint book-running managers for the offering.
The securities described above are being offered by the Company pursuant to a "shelf" registration statement previously filed with and declared effective by the Securities and Exchange Commission (SEC) on
, 2011. A prospectus supplement and an accompanying prospectus relating to the offering will be filed with the SEC in connection with the offering. Once filed, the prospectus supplement and accompanying prospectus may be obtained by sending a request to Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor,
New York, NY
10004, or by telephone at (212) 667-8563, or by email at
, or from Roth Capital Partners, LLC, Attention: Equity Capital Markets, 888 San Clemente Drive,
Newport Beach, CA
92660, (800) 678-9147,
, or by accessing the SEC's website at
Before investing in the offering, interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the company has filed with the SEC that are incorporated by reference in the prospectus supplement and the accompanying prospectus, which provide more information about the company and the offering.